These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17963091)

  • 1. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention.
    Shoptaw S; Rotheram-Fuller E; Landovitz RJ; Wang J; Moe A; Kanouse DE; Reback C
    AIDS Care; 2008 Mar; 20(3):376-81. PubMed ID: 17963091
    [No Abstract]   [Full Text] [Related]  

  • 2. Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center.
    Neu N; Heffernan-Vacca S; Millery M; Stimell M; Brown J
    Sex Transm Dis; 2007 Feb; 34(2):65-8. PubMed ID: 16794560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine + lamivudine: new preparation. Fewer tablets required.
    Prescrire Int; 1999 Apr; 8(40):39-40. PubMed ID: 10848057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
    Cournil A; Coudray M; Kouanfack C; Essomba CN; Tonfack CA; Biwolé-Sida M; Delaporte E; Bork K; Laurent C
    Antivir Ther; 2010; 15(7):1039-43. PubMed ID: 21041920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV post-exposure prophylaxis after sexual risk contact].
    Battegay M; Zimmerli W
    Schweiz Med Wochenschr; 1999 Feb; 129(8):311-3. PubMed ID: 10189667
    [No Abstract]   [Full Text] [Related]  

  • 6. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First combination drug for patients with HIV.
    Am Fam Physician; 1997 Dec; 56(9):2356. PubMed ID: 9402816
    [No Abstract]   [Full Text] [Related]  

  • 8. Tenofovir regimen compared with Combivir.
    AIDS Patient Care STDS; 2005 Jan; 19(1):59-60. PubMed ID: 15700398
    [No Abstract]   [Full Text] [Related]  

  • 9. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV postexposure prophylaxis after sexual assault: why is it so hard to accomplish?
    Cohen MS
    Sex Transm Dis; 2008 Dec; 35(12):979-80. PubMed ID: 18955917
    [No Abstract]   [Full Text] [Related]  

  • 11. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The management of the occupational exposures of health workers to HIV].
    Escribano Hernández A
    Aten Primaria; 1997 Jun; 20(1):54-6. PubMed ID: 9303664
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
    Fortes Déguénonvo L; Diop SA; Leye MM; Seydi M; Dieng AB; Bentaleb H; Diouf A; Lakhe NA; Ka D; Cisse VM; Dia Badiane NM; Manga MN; Ndour CT; Soumaré M; Diop BM; Sow PS
    Bull Soc Pathol Exot; 2013 Oct; 106(4):244-7. PubMed ID: 24150730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
    Rabaud C; Burty C; Grandidier M; Christian B; Penalba C; Béguinot I; Jeanmaire H; May T
    Clin Infect Dis; 2005 Jan; 40(2):303-5. PubMed ID: 15655751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of the TRIZAL Study. Therapy change with positive concomitant effect].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():51-2. PubMed ID: 11373781
    [No Abstract]   [Full Text] [Related]  

  • 17. Registry finds 3 drugs most favored PEP regimen.
    AIDS Alert; 1998 Jul; 13(7):75-6. PubMed ID: 11365586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
    Quirino T; Niero F; Ricci E; Pusterla L; Carradori S; Gabbuti A; Iemoli E; Landonio S; Faggion I; Bonfanti P;
    Antivir Ther; 2000 Sep; 5(3):195-7. PubMed ID: 11075939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piloting post-exposure prophylaxis in Kenya raises specific concerns for the management of childhood rape.
    Speight CG; Klufio A; Kilonzo SN; Mbugua C; Kuria E; Bunn JE; Taegtmeyer M
    Trans R Soc Trop Med Hyg; 2006 Jan; 100(1):14-8. PubMed ID: 16225898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Compact therapy with 2 tablets daily. Initial triple combination tablet simplifies HIV therapy].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():50-1. PubMed ID: 11373780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.